Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

Bibliography

• Zhang Q, Bhola NE, Lui VWI, Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007;19:1414-24
   Web of Science ®Google Scholar
• Yoo GH, Subramanian G, Piechocki MP, Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Arch Otolaryngol Head Neck Surg 2008;134(7):735-42
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Mork J, Lie AK, Glattre E, Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344(15):1125-31
   PubMed Web of Science ®Google Scholar
• Furniss CS, McClean MD, Smith JF, Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007;120(11):2386-92
   PubMed Web of Science ®Google Scholar
• Khuri FR, Kim ES, Lee JJ, The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10(8):823-9
   PubMed Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22(9):1743-52
   PubMed Web of Science ®Google Scholar
• Psyrri A, Kwong M, DiStasio S, Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-Up. J Clin Oncol 2004;22(15):3061-9
   PubMed Web of Science ®Google Scholar
• Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24(17):2666-72
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor {alpha} and epidermal growth factor receptor messenger rna are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84
   PubMed Web of Science ®Google Scholar
• Grandis JR, Melhem MF, Gooding WE, Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824-32
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6
   PubMed Web of Science ®Google Scholar
• Grandis JR, Chakraborty A, Melhem MF, Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997;15:409-16
   PubMed Web of Science ®Google Scholar
• Erjala K, Sundvall M, Junttila TT, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to egfr inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12(13):4103-11
   PubMed Web of Science ®Google Scholar
• Nozawa H, Tadakuma T, Ono T, Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006;97(10):1115-24
   PubMed Web of Science ®Google Scholar
• Seethala RR, Gooding WE, Handler PN, Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 2008;14(5):1303-9
   PubMed Web of Science ®Google Scholar
• Thomas SM, Bhola NE, Zhang Q, Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66(24):11831-9
   PubMed Web of Science ®Google Scholar
• Alhasan SA, Aranha O, Sarkar FH. Genistein Elicits Pleiotropic Molecular Effects on Head and Neck Cancer Cells. Clinical Cancer Research 2001;7(12):4174-81
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9(7):463-75
   PubMed Web of Science ®Google Scholar
• Yotsumoto F, Yagi H, Suzuki SO, Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008;365(3):555-61
   PubMed Web of Science ®Google Scholar
• Dawson JP, Bu Z, Lemmon MA. Ligand-induced structural transitions in erbb receptor extracellular domains. Structure 2007;15(8):942-54
   PubMed Web of Science ®Google Scholar
• Ferguson KM. Structural aspects of extracellular EGFR signaling. FASEB J 2009;23(1_Meeting Abstracts): 198.3
   Google Scholar
• Schmitz KR, Ferguson KM. Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 2009;315(4):659-70
   PubMed Web of Science ®Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008;16(2):216-27
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125(6):1137-49
   PubMed Web of Science ®Google Scholar
• Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1-13
   Web of Science ®Google Scholar
• Zhang Q, Thomas SM, Lui VW, Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. PNAS 2006;103(18):6901-6
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27(28):3944-56
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-6
   PubMed Web of Science ®Google Scholar
• Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42(1):109-11
   PubMed Web of Science ®Google Scholar
• Frederick BA, Helfrich BA, Coldren CD, Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma. Mol Cancer Ther 2007;6(6):1683-91
   PubMed Web of Science ®Google Scholar
• Chung CH, Parker JS, Ely K, Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66(16):8210-18
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• Matar P, Rojo F, Cassia R, Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225). Clin Cancer Res 2004;10(19):6487-501
   PubMed Web of Science ®Google Scholar
• Zhang Q, Thomas SM, Xi S, Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64(17):6166-73
   PubMed Web of Science ®Google Scholar
• Yoshida T, Okamoto I, Iwasa T, The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett 2008;582(30):4125-30
   PubMed Web of Science ®Google Scholar
• Mandic R, Rodgarkia-Dara CJ, Zhu L, Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux®) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 2006;580(20):4973-800
   Web of Science ®Google Scholar
• Friedman LM, Rinon A, Schechter B, Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 2005;102(6):1915-20
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133(12):1277-81
   PubMed Web of Science ®Google Scholar
• Bocci G, Man S, Green SK, Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004;64(18):6616-25
   PubMed Web of Science ®Google Scholar
• Ebos JML, Lee CR, Christensen JG, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104(43):17069-74
   PubMed Web of Science ®Google Scholar
• Almand B, Resser JR, Lindman B, Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6(5):1755-66
   PubMed Web of Science ®Google Scholar
• Mickel RA, Kessler DJ, Taylor JM, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988;48(17):5017-22
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21(21):3940-7
   PubMed Web of Science ®Google Scholar
• Wu X, Rubin M, Fan Z, Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12(7):1397-403
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Shin DM, Donato NJ, Perez-Soler R, Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7(5):1204-13
   PubMed Web of Science ®Google Scholar
• Robert F, Ezekiel MP, Spencer SA, Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(13):3234-43
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Bonner JA, Raisch KP, Trummell HQ, Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18(Suppl 1):47S-53S
   PubMed Web of Science ®Google Scholar
• Bonner JA, Giralt J, Harari PM, Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S):5507
   Google Scholar
• Huether A, Höpfner M, Baradari V, EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70(11):1568-78
   PubMed Web of Science ®Google Scholar
• Li D, Ji H, Zaghlul S, Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas. J Clin Invest 2007;117(2):346-52
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277(48):46265-72
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306–11
   PubMed Web of Science ®Google Scholar
• Balak MN, Gong Y, Riely GJ, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12(21):6494-501
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Sequist LV, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(13):3908-14
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118(2):257-62
   PubMed Web of Science ®Google Scholar
• Patel V, Ramesh A, Traicoff JL, Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane western blot technology. Oral Oncol 2005;41(5):503-8
   PubMed Web of Science ®Google Scholar
• Feng FY, Lopez CA, Normolle DP, Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 2007;13(8):2512-18
   PubMed Web of Science ®Google Scholar
• Bruzzese F, Di Gennaro E, Avallone A, Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2006;12(2):617-25
   PubMed Web of Science ®Google Scholar
• Pollack VA, Savage DM, Baker DA, Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291(2):739-48
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Wheeler RH, Jones D, Sharma P, Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005;23(Suppl 16):5531
   Web of Science ®Google Scholar
• Doss HH, Greco FA, Meluch AA, Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of the Minnie Pearl Cancer Research Network [abstract]. J Clin Oncol 2006;24(Suppl 18):5543
   Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27(11):1864-71
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Kalish LH, Kwong RA, Cole IE, Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10(22):7764-74
   PubMed Web of Science ®Google Scholar
• Gee JE, Robbins I, van der Laan AC, Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1998;8(2):103-11
   PubMedGoogle Scholar
• Griffey RH, Monia BP, Cummins LL, 2′-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J Med Chem 1996;39(26):5100-9
   PubMed Web of Science ®Google Scholar
• He Y, Zeng Q, Drenning SD, Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998;90(14):1080-7
   PubMed Web of Science ®Google Scholar
• Endo S, Zeng Q, He Y, TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther 2000;7(22):1906-14
   PubMed Web of Science ®Google Scholar
• Thomas SM, Ogagan MJ, Freilino ML, Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73(3):627-38
   PubMed Web of Science ®Google Scholar
• Ketting RF, Fischer SE, Bernstein E, Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001;15(20):2654-9
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15(2):188-200
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvágner G, Du T, Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115(2):199-208
   PubMed Web of Science ®Google Scholar
• Song JJ, Smith SK, Hannon GJ, Crystal structure of argonaute and its implications for RISC slicer activity. Science 2004;305(5689):1434-7
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N, Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313(5998):144-7
   PubMed Web of Science ®Google Scholar
• Kang CS, Zhang ZY, Jia ZF, Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther 2006;13(5):530-8
   PubMed Web of Science ®Google Scholar
• Fan Q-W, Weiss WA. RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 2004;24(5):829-37
   Web of Science ®Google Scholar
• Morris MJ, Tong WP, Cordon-Cardo C, Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8(3):679-83
   PubMed Web of Science ®Google Scholar
• Lai SY, Koppikar P, Thomas SM, Intratumoral epidermal growth factor receptor antisense dna therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009;27(8):1235-42
   PubMed Web of Science ®Google Scholar
• Bachran C, Sutherland M, Bachran D, Fuchs H. Quantification of diphtheria toxin mediated ADP-ribosylation in a solid-phase assay. Clin Chem 2007;53(9):1676-83
   PubMed Web of Science ®Google Scholar
• Phillips PC, Levow C, Catterall M, Transforming growth factor-{alpha} Pseudomonas exotoxin fusion protein (TGF-{alpha}-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 1994;54(4):1008-15
   PubMed Web of Science ®Google Scholar
• Thomas SM, Zeng Q, Epperly MW, Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to Pseudomonas exotoxin transforming growth factor alpha-PE38. Clin Cancer Res 2004;10(20):7079-87
   PubMed Web of Science ®Google Scholar
• Riechelmann H, Sauter A, Golze W, Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2007;44(9):823-9
   Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68(22):9280-90
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65(1):27-35
   PubMed Web of Science ®Google Scholar
• Hitt R, Ciruelos E, Amador ML, Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41(3):453-60
   PubMed Web of Science ®Google Scholar
• Koppikar P, Choi SH, Egloff AM, Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14(13):4284-91
   PubMed Web of Science ®Google Scholar
• Leeman-Neill RJ, Wheeler SE, Singh SV, Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30(11):1848-56
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68(20):8322-32
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Jagadeeswaran R, Faoro L, The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009;69(7):3021-31
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Phase I study of bortezomib plus cetuximab in patients with tumors expressing epidermal growth factor receptor (EGFR) [abstract]. J Clin Oncol 2007;25(Suppl 18):18143
   Web of Science ®Google Scholar
• Wanebo HJ, Ghebremichael M, Burtness B, Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]. J Clin Oncol 2007;25(Suppl 18):6015
   Web of Science ®Google Scholar
• Wirth LJ, Posner MR, Tishler RB, Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): early results [abstract]. J Clin Oncol 2007;25(Suppl 18):6083
   Web of Science ®Google Scholar
• Bonner JA, Giralt J, Harari PM, Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol 2004;22(Suppl 14):5507
   Web of Science ®Google Scholar
• Altorki NK, Keresztes RS, Port JL, Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21(14):2645-50
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
   PubMed Web of Science ®Google Scholar
• Savvides P, Agarwala SS, Greskovich J, Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. J Clin Oncol 2006;24(Suppl 18):5545
   PubMed Web of Science ®Google Scholar
• Sharp H, Morris JC, Van Waes C, High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. Am J Clin Oncol 2008;31(6):557-60
   PubMed Web of Science ®Google Scholar
• Specenier PM, Lalami Y, Vermorken J, EORTC 24051: unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC) [abstract]. J Clin Oncol 2009;27(15S):6017
   Google Scholar